Endometrial Cancer
Conditions
Keywords
Endometrial Cancer
Brief summary
This research study is studying a drug combination as a possible treatment for endometrial cancer. The drugs involved in this study are: * mirvetuximab soravtansine (IMGN853) * pembrolizumab
Detailed description
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has not approved mirvetuximab soravtansine for this specific disease but it has been approved for other uses. The FDA (the U.S. Food and Drug Administration) has not approved pembrolizumab for this specific disease but it has been approved for other uses. In this research study, the investigators are studying the combination of mirvetuximab soravtansine and pembrolizumab. Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells. Pembrolizumab by itself may not be enough to kill cancer cells in all people with cancer. In this study, all patients will receive mirvetuximab soravtansine and pembrolizumab. Mirvetuximab soravtansine is an antibody-drug conjugate. That is a type of agent that attaches a chemotherapy drug to a molecule that binds a protein on the outside of cancer cells. The protein targeted by mirvetuximab soravtansine is called folate receptor-alpha (FRα). FRα is expressed on the surface of certain cancers, including endometrial cancer cells. Mirvetuximab soravtansine is expected to kill cancer cells by delivering chemotherapy to cells that have high levels of FRα. To participate in this study, a sample of your tumor was previously tested, and was found to have high levels of FRα. Mirvetuximab soravtansine also may also active immune cells and improve the response to immunotherapies like pembrolizumab. In this study, the investigators expect to learn whether the combination of pembrolizumab and mirvetuximab soravtansine can shrink endometrial cancers or prevent their growth for at least 6 months. The investigators will also learn more about the side effects patients experience who receive this treatment. The investigators also plan to learn more about which patients are likely to benefit from this treatment
Interventions
DRUGPembrolizumab
Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells
DRUGIMGN853
Mirvetuximab soravtansine is an antibody-drug conjugate.
Sponsors
Dana-Farber Cancer Institute
ImmunoGen, Inc.
Merck Sharp & Dohme LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants must have advanced or recurrent serous endometrial cancer. Patients with mixed histologies/tumors are eligible if the serous component is the dominant histological subtype. In addition, the tumors must be: * microsatellite stable (MSS) as documented by either intact immunohistochemical (IHC) nuclear expression of the mismatch repair genes MSH2, MSH6, MLH1 and PMS2; or microsatelitte stable by polymerase chain reaction (PCR), next generation sequencing, or other CLIA-approved method; AND * FRα positive by central immunohistochemistry (IHC, Section 9.1). If archival tissue does not meet FRα criteria, a fresh biopsy tumor sample may be submitted and used to meet this criterium. If a fresh tumor biopsy cannot be done safely the patient will not be allowed to enroll on this study. * Participants must have measurable disease as defined by RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. * Prior therapy: Patients must have had one, but no more than three lines of chemotherapy for endometrial carcinoma. * Prior hormonal therapy is allowed (no washout period is required after hormonal therapy) and does not count as a prior line of therapy. Hormonal therapy in combination with CDK4/6 inhibitors or mTOR or other PI3K-pathway inhibitors is allowed and does not count as a line of prior therapy. * Prior IO therapy targeted to the PD-1/PD-L1 pathway is allowed in up to 19 patients of the total cohort. * Patients must NOT have received prior therapy with any folate receptor ortholog agents. * Age 18 or greater years. Because insufficient dosing or adverse event data are currently available on the use of mirvetuximab soravtansine and pembrolizumab in participants \<18 years of age, children are excluded. Endometrial cancer is rare in the pediatric population. * ECOG performance status 0 or 1 * Participants must have normal organ and marrow function as defined below: * leukocytes ≥3,000/mcL * absolute neutrophil count ≥1,500/mcL * platelets ≥100,000/mcL * hemoglobin ≥ 9.0 g/dL * total bilirubin ≤ 1.5 x institutional upper limit of normal * AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal * creatinine ≤ institutional upper limit of normal OR * creatinine clearance ≥40 mL/min/1.73 m2 for participants with creatinine levels above institutional normal. -Time from prior therapy: * Systemic anti-neoplastic therapy: 5 half-lives or 4 weeks, whichever is shorter. Hormonal therapy is not considered anti-neoplastic therapy. * Radiotherapy: wide-field radiotherapy (e.g. \> 30% of marrow-bearing bones) completed at least 4 weeks, or focal radiation completed at least 2 weeks, prior to starting study treatment * The effects of agents used in this study on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during study treatment, and for at least twelve weeks after the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. * Women of child-bearing potential must have a negative serum pregnancy test within 3 days prior to the first dose of study treatment. * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Participants who have had chemotherapy within 5 half-lives or 4 weeks (whichever is shorter) or radiotherapy within 2 weeks prior to entering the study. Patients completing wide-field radiotherapy (e.g. \>30% of marrow-bearing bones) must not have had treatment within 4 weeks prior to entering study. Participants must have recovered from all AEs due to previous therapy to Grade 1 ≤ or baseline, except alopecia. Participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible. * Participants who are receiving any other investigational agents. * Participants with prior exposure to IO agents targeting the PD-1/PD-L1 pathway who discontinued therapy due to treatment-related toxicity deemed to be specifically related to IO therapy. * Required use of folate-containing supplements (e.g. folate deficiency). * Known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to monoclonal antibodies (including antibody drug-conjugates or checkpoint inhibitors). * Uncontrolled intercurrent illness including, but not limited to, any of the following within 6 months of first study treatment: symptomatic congestive heart failure, unstable angina pectoris, uncontrolled hypertension (≥ Grade 3), hypertensive crisis or hypertensive encephalopathy, uncontrolled cardiac arrhythmias, thrombotic or ischemic stroke, clinically-significant vascular disease (e.g. aortic aneurysm, or dissecting aneurysm), severe aortic stenosis, clinically significant peripheral vascular disease, or ≥ Grade 3 cardiac toxicity following prior chemotherapy, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Active or chronic corneal disorder, including but not limited to the following: Sjogren's syndrome, Fuchs corneal dystrophy (requiring treatment), history of corneal transplantation, active herpetic keratitis, and also active ocular conditions requiring on-going treatment/monitoring such as wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, presence of papilledema, and acquired monocular vision. * Serious clinically-relevant active infection, including known HIV infection, varicella-zoster virus, cytomegalovirus infection, has a known history of Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) or any other known concurrent infectious disease requiring IV antibiotics with within 2 weeks of study enrollment are ineligible because of the potential for immune side effects. * Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. * Current or prior use of immunosuppressive medication within 7 days prior to enrollment with the following exceptions to this exclusion criterion: * Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection); * Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent; * Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication). * Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, hypo-or hyperthyroid disease not requiring immunosuppressive treatment are eligible. * Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis. * Pregnant or nursing women are excluded from this study because effects of agents used in this study on infants or the developing human fetus are unknown * Presence of other malignancies unless they are considered cured by patient's oncologist
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | 6 months | The objective response rate was determined by the frequency of patients who had objective tumor response, determined per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI, where objective response represents either a confirmed complete response (CR; disappearance of all target lesions) or a confirmed partial response (PR; at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum diameters); objective response = CR + PR. The ORR is therefore reported as the percentage of participants who achieved a CR or PR per RECIST v1.1. |
| Progression-Free Survival at 6 Months (PFS6) | 6 months | Progression-free survival at 6 months was determined by the frequency of patients who survived progression-free for at least 6 months after initiating study treatment by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), where disease progression represents at least a 20% increase in the sum of diameters of target lesions, appearance of one or more new lesions, or unequivocal progression of existing non-target lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival | Interval from start of treatment to documented disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurs first. | Progression-free survival was determined per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), where disease progression represents at least a 20% increase in the sum of diameters of target lesions, appearance of one or more new lesions, or unequivocal progression of existing non-target lesions. The distribution of progression-free times will be estimated using Kaplan-Meier analysis. |
| Overall Survival | Participants are followed for survival status from registration through up to 3 years after removal from study intervention | Overall survival (OS) is defined as the time from registration to death due to any cause, or censored at date last known alive. The distribution of overall survival times will be estimated using Kaplan-Meier analysis. |
| Duration of Response | Interval from best overall response to documented disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurs first. | Duration of response (DoR) is defined as time from best overall response to the time of disease progression. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORRebecca Porter, MD, PhD
Dana-Farber Cancer Institute
Participant flow
Pre-assignment details
Of the 18 participants enrolled, all 18 participants are considered evaluable for assessment. Enrollment was closed before the total accrual goal of 35 was met.
Participants by arm
| Arm | Count |
|---|---|
| IMGN853 + Pembrolizumab * Pembrolizumab is administered intravenously once every 3 weeks
* IMGN853 is administered intravenously once every 3 weeks
Pembrolizumab: Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells
IMGN853: Mirvetuximab soravtansine is an antibody-drug conjugate. | 18 |
| Total | 18 |
Baseline characteristics
| Characteristic | IMGN853 + Pembrolizumab |
|---|---|
| Age, Continuous | 68.3 years STANDARD_DEVIATION 5.05 |
| ECOG Performance Status 00 - Fully active | 12 Participants |
| ECOG Performance Status 01 - Restricted | 6 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 16 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Prior Anti-PD-1/PD-L1 Exposure IO-exposed (avelumab) | 1 Participants |
| Prior Anti-PD-1/PD-L1 Exposure IO-exposed (dostarlimab) | 1 Participants |
| Prior Anti-PD-1/PD-L1 Exposure IO-exposed (pembrolizumab) | 6 Participants |
| Prior Anti-PD-1/PD-L1 Exposure IO-naïve | 10 Participants |
| Prior Lines 1 | 2 Participants |
| Prior Lines 2 | 7 Participants |
| Prior Lines 3 | 5 Participants |
| Prior Lines 4 | 4 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 15 Participants |
| Sex: Female, Male Female | 18 Participants |
| Sex: Female, Male Male | 0 Participants |
| Stage at Initial Diagnosis Stage I | 5 Participants |
| Stage at Initial Diagnosis Stage II | 0 Participants |
| Stage at Initial Diagnosis Stage III | 7 Participants |
| Stage at Initial Diagnosis Stage IV | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 12 / 18 |
| other Total, other adverse events | 18 / 18 |
| serious Total, serious adverse events | 4 / 18 |
Outcome results
Primary
Objective Response Rate
The objective response rate was determined by the frequency of patients who had objective tumor response, determined per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI, where objective response represents either a confirmed complete response (CR; disappearance of all target lesions) or a confirmed partial response (PR; at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum diameters); objective response = CR + PR. The ORR is therefore reported as the percentage of participants who achieved a CR or PR per RECIST v1.1.
Time frame: 6 months
Population: Among 18 patients, 5 had a confirmed response. Confirmed ORR is 28%, with 95% confidence interval of \[ 10%, 53%\].
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| IMGN853 + Pembrolizumab | Objective Response Rate | 28 percentage of participants |
Primary
Progression-Free Survival at 6 Months (PFS6)
Progression-free survival at 6 months was determined by the frequency of patients who survived progression-free for at least 6 months after initiating study treatment by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), where disease progression represents at least a 20% increase in the sum of diameters of target lesions, appearance of one or more new lesions, or unequivocal progression of existing non-target lesions.
Time frame: 6 months
Population: 4 patients were alive and progression-free at 6 months.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| IMGN853 + Pembrolizumab | Progression-Free Survival at 6 Months (PFS6) | 4 Participants |
Secondary
Duration of Response
Duration of response (DoR) is defined as time from best overall response to the time of disease progression.
Time frame: Interval from best overall response to documented disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurs first.
Population: Due to the small number of responses, reporting the confidence interval or interquartile range is not meaningful. Out of the 5 confirmed responders, 2 experienced events (progression or death), while 3 were censored.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| IMGN853 + Pembrolizumab | Duration of Response | 7.1 months |
Secondary
Overall Survival
Overall survival (OS) is defined as the time from registration to death due to any cause, or censored at date last known alive. The distribution of overall survival times will be estimated using Kaplan-Meier analysis.
Time frame: Participants are followed for survival status from registration through up to 3 years after removal from study intervention
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| IMGN853 + Pembrolizumab | Overall Survival | 11.3 months |
Secondary
Progression-free Survival
Progression-free survival was determined per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), where disease progression represents at least a 20% increase in the sum of diameters of target lesions, appearance of one or more new lesions, or unequivocal progression of existing non-target lesions. The distribution of progression-free times will be estimated using Kaplan-Meier analysis.
Time frame: Interval from start of treatment to documented disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurs first.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| IMGN853 + Pembrolizumab | Progression-free Survival | 2.73 months |